Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U1 small nuclear RNA is an essential component of the spliceosome complex, required for the splicing of pre-mRNA in eukaryotes[1][2]. U1 snRNA mediates recognition of the 5' splice site on pre-mRNA and is crucial for initiating spliceosome assembly and regulated gene expression[1][2]. The RNU1-19P locus is a pseudogene: a DNA sequence with close similarity to active U1 snRNA genes but containing mutations or deletions preventing it from encoding the canonical snRNA[1][3]. Pseudogenes of U1 snRNA, such as RNU1-19P, are typically located in the 1q12–21 region of chromosome 1 and are considered "class I" pseudogenes[1][3]. Historically, such pseudogenes were presumed non-functional, but recent evidence suggests some U1 snRNA pseudogenes can be transcribed and may produce variant snRNA molecules that play regulatory roles in mRNA processing. However, for RNU1-19P specifically, there is no evidence for direct functional activity, no validated disease association, and it is not a therapeutic target[1]. Interpretation and notes: - This target is a pseudogene, not a canonical receptor, enzyme, transporter, or transcription factor. - There are no drugs or clinical biomarkers associated with this entity. - It should be considered not a therapeutic target. - The symbol/name suggests it could be confused with functional U1 snRNA or with U1 snRNP (spliceosome protein complex), which are essential for splicing, but RNU1-19P itself is not a functional target[1][3]. - Pseudogenes may be transcribed and could conceivably have regulatory functions, but there is no direct evidence for this specific locus.
Not applicable; no approved drugs target this pseudogene
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U1 small nuclear RNA 19, pseudogene (RNU1-19P).